# PARERE (NCT04787341)

> PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04787341
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Gruppo Oncologico del Nord-Ovest
- Conditions: Colorectal Cancer
- Interventions: Regorafenib; Panitumumab
- Enrollment: 213
- Primary outcome: Overall survival

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 19
- YouTube: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=parere-nct04787341

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04787341", "email": "<work email>"}; the inbox owner confirms by the emailed link.